OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Want to cut your energy bills? Here’s how five experts are doing it 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
EMERYVILLE, Calif., May 31, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will present a corporate overview at the Jefferies 2017 Global Healthcare Conference, taking place on June 6-9, 2017, in New York, NY.
Zogenix Presentation Details
| Date: | Wednesday, June 7, 2017 |
| Time: | 2:00 pm Eastern Time / 11:00 am Pacific Time |
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
